Mersana Historical Financial Ratios
| MRSN Stock | USD 2.21 0.31 12.30% |
Mersana Therapeutics is lately reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 389 will help investors to properly organize and evaluate Mersana Therapeutics financial condition quickly.
Mersana |
About Mersana Financial Ratios Analysis
Mersana TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Mersana Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Mersana financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Mersana Therapeutics history.
Mersana Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Mersana Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Mersana Therapeutics sales, a figure that is much harder to manipulate than other Mersana Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Net Debt To E B I T D A
A leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).Current Ratio
A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.Most ratios from Mersana Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Mersana Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.At this time, Mersana Therapeutics' PTB Ratio is very stable compared to the past year. As of the 16th of November 2024, Days Sales Outstanding is likely to grow to 389.29, while Price To Sales Ratio is likely to drop 6.94.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 3.97 | 3.49 | 3.36 | 2.94 | Net Debt To EBITDA | 0.83 | 1.22 | 0.85 | 0.81 |
Mersana Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Mersana Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mersana Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.9 | 2.0K | 10.2K | 20.65 | 7.31 | 6.94 | |
| Ptb Ratio | 3.18 | 7.17 | 3.61 | 5.96 | 7.3 | 7.66 | |
| Book Value Per Share | 1.8 | 3.71 | 1.72 | 0.98 | 0.32 | 0.3 | |
| Free Cash Flow Yield | (0.6) | (0.27) | (0.0459) | (0.32) | (0.0939) | (0.63) | |
| Operating Cash Flow Per Share | (1.56) | (1.21) | (1.98) | (0.53) | (1.45) | (1.53) | |
| Stock Based Compensation To Revenue | 0.12 | 8.66 | 428.12 | 0.81 | 0.57 | 0.54 | |
| Capex To Depreciation | 0.49 | 0.47 | 0.76 | 2.37 | 1.43 | 1.42 | |
| Pb Ratio | 3.18 | 7.17 | 3.61 | 5.96 | 7.3 | 7.66 | |
| Ev To Sales | 4.61 | 1.7K | 7.0K | 11.45 | 3.49 | 3.32 | |
| Free Cash Flow Per Share | (1.57) | (1.22) | (1.99) | (0.55) | (1.47) | (1.55) | |
| Roic | (0.34) | (0.38) | (1.15) | (1.77) | (2.75) | (2.89) | |
| Net Income Per Share | (0.63) | (1.44) | (2.4) | (2.22) | (1.48) | (1.55) | |
| Payables Turnover | 7.54 | 8.04 | 10.71 | 0.0664 | 20.26 | 21.27 | |
| Sales General And Administrative To Revenue | 0.41 | 26.45 | 857.86 | 2.14 | 1.62 | 1.53 | |
| Research And Ddevelopement To Revenue | 1.31 | 80.96 | 3.1K | 6.52 | 4.02 | 3.82 | |
| Capex To Revenue | 0.0144 | 0.57 | 15.07 | 0.0827 | 0.0588 | 0.0559 | |
| Cash Per Share | 2.3 | 4.15 | 2.52 | 4.62 | 1.8 | 1.71 | |
| Pocfratio | (3.67) | (21.9) | (3.14) | (11.12) | (1.6) | (1.67) | |
| Capex To Operating Cash Flow | (0.008931) | (0.006332) | (0.004629) | (0.0445) | (0.0128) | (0.0135) | |
| Pfcf Ratio | (3.64) | (21.77) | (3.12) | (10.64) | (1.57) | (1.65) | |
| Days Payables Outstanding | 48.38 | 45.41 | 34.07 | 5.5K | 18.02 | 17.12 | |
| Income Quality | 2.4 | 0.85 | 0.82 | 0.24 | 0.98 | 0.5 | |
| Roe | (0.35) | (0.39) | (1.39) | (2.25) | (4.65) | (4.42) | |
| Ev To Operating Cash Flow | (2.86) | (18.71) | (2.14) | (6.17) | (0.76) | (0.8) | |
| Pe Ratio | (9.14) | (18.51) | (2.59) | (2.64) | (1.57) | (1.65) | |
| Return On Tangible Assets | (0.82) | (0.25) | (0.32) | (0.62) | (0.76) | (0.8) | |
| Ev To Free Cash Flow | (2.84) | (18.59) | (2.13) | (5.9) | (0.75) | (0.79) | |
| Earnings Yield | (0.11) | (0.054) | (0.39) | (0.38) | (0.64) | (0.67) | |
| Net Debt To E B I T D A | 2.04 | 2.75 | 0.83 | 1.22 | 0.85 | 0.81 | |
| Current Ratio | 4.21 | 8.62 | 3.97 | 3.49 | 3.36 | 2.94 | |
| Tangible Book Value Per Share | 1.8 | 3.71 | 1.72 | 0.98 | 0.32 | 0.3 | |
| Graham Number | 5.04 | 10.95 | 9.65 | 7.0 | 3.25 | 3.09 | |
| Shareholders Equity Per Share | 1.8 | 3.71 | 1.72 | 0.98 | 0.32 | 0.3 | |
| Capex Per Share | 0.0139 | 0.007693 | 0.009181 | 0.0235 | 0.0187 | 0.0177 | |
| Graham Net Net | 1.63 | 3.41 | 1.33 | 2.27 | 0.17 | 0.16 |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.87 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | VCNX | Vaccinex | PairCorr |
| 0.53 | ME | 23Andme Holding | PairCorr |
| 0.53 | DTIL | Precision BioSciences | PairCorr |
| 0.49 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.247 | Quarterly Revenue Growth (0.79) | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.